Fluconazole resistant oral candidiasis in HIV-infected patients

Oral Dis. 1997 May:3 Suppl 1:S110-2. doi: 10.1111/j.1601-0825.1997.tb00337.x.

Abstract

Objective: To evaluate the risk factors associated with the emergence of fluconazole resistant Candida spp. in HIV-infected patients with oral candidiasis.

Methods: Candida spp. were isolated from oral swabs and tested in vitro for resistance to fluconazole. The factors potentially correlated with vazole-resistent Candida spp. infections were investigated.

Results: Fifty-one out of 118 patients (43%) with oral candidiasis had fluconazole resistant Candida spp. The following factors were significantly associated with the development of fluconazole resistance: (1) more than five episodes of oral candidiasis in the previous year (P < 0.001); (2) fluconazole therapy in the previous 6 months (P < 0.001); (3) C3 category of HIV infection (P < 0.001); and (4) low number of TCD4+ cells (< 50 mm3, P = 0.002). According to multivariate analysis, previous therapy with fluconazole was the only risk factor that independently influenced the development of Candida spp. resistance (P = 0.003).

Conclusions: The prophylaxis and therapy of mild fungal infections in HIV-infected patients, which may lead to azole resistance, should be carefully considered.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Candida / drug effects
  • Candidiasis, Oral / drug therapy*
  • Candidiasis, Oral / etiology
  • Case-Control Studies
  • Chi-Square Distribution
  • Drug Resistance, Microbial
  • Fluconazole / pharmacology*
  • Fluconazole / therapeutic use*
  • HIV Infections / classification
  • HIV Infections / complications*
  • Humans
  • Logistic Models
  • Multivariate Analysis
  • Patient Care Planning
  • Patient Selection
  • Risk Factors

Substances

  • Antifungal Agents
  • Fluconazole